Menu
CytoVeris is developing AI-powered cancer imaging technology that can deliver real-time cancer tissue visualization, enabling more precise intraoperative decisions and improving patient outcomes
The Data Tells us we Need to Improve the Precision of Cancer Resection
Breast Conservation Surgeries (BCS)
Up
to
35%
15-35% of BCS lumpectomies require a second surgery which often presents increased risk of complications ²
Transurethral Resection of Bladder Tumor (TURBT)
50%
of TURBT resections are incomplete, contributing to a higher risk of residual disease, early recurrence, and increased mortality¹
Radical Prostatectomies (RP)
25%
of RP procedures result in positive surgical margins, leading to a 2 to 3 fold increased in risk of biochemical recurrence³
1. Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
2. A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
3. Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011
- Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link. K Chamie, et al. 3, 2015, Cancer, Vol. 121
- A randomized, controlled trial of Cavity Shave margins in breast cancer. Chagpar, A. B et al. (2015). New England Journal of Medicine, 373(6)
- Frequency of Positive Surgical Margin at Prostatectomy and Its Effect on Patient Outcome. K. Iczkowski, M. Scott. Prostate Cancer, Vol. 2011
A 60% reduction in the breast cancer positive margin rate nationwide could avoid reoperations for 30,000 women annually.
Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization
The Tumor Margin Assessment and Profiling System, TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.
All without the use of an imaging agent
Enabling SMARTER, more EFFICIENT, and more EFFECTIVE surgical visualization
The Tumor Margin Assessment and Profiling System, TumorMAP™ is a multispectral imaging (MSI), Ultra high-definition (UHD), real-time intraoperative cancer imaging solution. TumorMAP produces an ultra-violet-excited autofluorescence image that enables surgeons to visually assess tissue that is indicative of cancer, based on changes in metabolism and tissue microstructure between healthy and unhealthy tissues.
All without the use of an imaging agent
AI POWERED - INTUITIVE OUTPUT
No DYE
REAL-TIME
INCREASED PRECISION
intraoperative tissue insights increase margin accuracy
SEAMLESS FIT w/WORKFLOW
intra-operative efficiency require fewer resources
COST SAVINGS
of secondary operations & additional treatments
better outcomes
fewer complications, re-operations, radiation therapy, better functional outcomes
CytoVeris is aligned with the OR of the future
REAL-TIME
Easy to interpret tools to visualize cancer tissue in real-time during surgery and enable faster decisions
DATA
The future of surgery is DIGITAL – real-time information to surgeons to enhance intraoperative decision-making
PERSONALIZED
Accurate margin data allows customization of the surgical procedure to each patient’s needs
ROBOTICS
Platform technology presents ability to integrate TumorMAP™ imaging into robotics surgical procedures
CytoVeris' Platform Technology, TumorMAP™ powered by OncoSIGHT AI™ relies on the intersection of the natural biochemical characteristics of tissue, multispectral imaging and AI, and is under development to make a difference for patients across multiple disease areas.
OncoSIGHT AI™ is a proprietary, next generation tissue characterization algorithm that provides a safer, smarter and more reliable visualization of tissue indicative of cancer. cancerous tissue.
>> CLICK HERE TO LEARN MORE ABOUT ONCOSIGHT AI
Indication
Pre-clinical research
OncoSIGHT AI training
OncoSIGHT AI validation
Feasibility Study
Pivotal Study
FDA Approval
breast
bladder
PROSTATE
CytoVeris is proving what’s possible during cancer surgery.
Be the first to know
Find Us
-
400 Farmington Ave.
Farmington, CT 06032
Contact Us
Media inquiries, please contact
[email protected]
Copyright © 2022 CytoVeris Inc. All rights reserved.